NASDAQ: LSTA - Lisata Therapeutics, Inc.

Yield per half year: -21.67%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Lisata Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.

more details
Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1999-03-01
ISIN US1280583022
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lisata.com
Цена ао 2.43
Change price per day: -2.51% (2.4104)
Change price per week: -1.26% (2.38)
Change price per month: -1.67% (2.39)
Change price per 3 month: -22.19% (3.0201)
Change price per half year: -21.67% (3)
Change price per year: -24.68% (3.12)
Change price per 3 year: +201.28% (0.78)
Change price per 5 year: -0.4237% (2.36)
Change price per year to date: -24.07% (3.095)
All parameters

Underestimation

Title Value Grade
P/S 0.1067 10
P/BV 0.477 10
P/E 0 0
EV/EBITDA -0.0219 0
Total: 6.25

Efficiency

Title Value Grade
ROA, % -38.1 0
ROE, % -43.28 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.012 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 727.43 10
Yield Ebitda, % 32.22 5
Yield EPS, % -91.16 0
Total: 3.4
More

Institutions Volume Share, %
Bml Capital Management, LLC 269839 3.25
Vanguard Group Inc 176965 2.13
Renaissance Technologies, LLC 97222 1.17
Blackrock Inc. 56250 0.68
Geode Capital Management, LLC 43390 0.52
Susquehanna International Group, LLP 33749 0.41
State Street Corporation 14348 0.17
Citadel Advisors Llc 14131 0.17
Cook Wealth Management Group LLC 12175 0.15
HighTower Advisors, LLC 10044 0.12



Head Job title Payment Year of birth
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. President, CEO & Director 1.16M 1957 (68 years)
Dr. Kristen K. Buck M.D. Executive VP of R&D and Chief Medical Officer 938.42k 1974 (51 year)
Mr. James Nisco Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer N/A 1971 (54 years)
Mr. Tariq Imam Vice President of Business Development & Operations and Corporate Counsel N/A
Mr. Gregory S. Berkin Chief Information Officer N/A
Mr. John D. Menditto Vice President of Investor Relations & Corporate Communications N/A
Ms. Gail Holler Vice President of Human Resources N/A 1959 (66 years)
Dr. William K. Sietsema Ph.D. Vice President of Global Regulatory Affairs 350.55k 1956 (69 years)

Address: United States, Basking Ridge. NJ, 110 Allen Road - open in Google maps, open in Yandex maps
Website: https://www.lisata.com